Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer
Status:
Withdrawn
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
In 2008 there were more than 40,000 deaths caused by metastatic breast cancer in the United
States. The development of new treatment strategies is essential to improve outcome for
patients with metastatic breast cancer
There is significant preclinical and clinical evidence indicating that creating new blood
vessels (neoangiogenesis) to provide nutrients to solid tumors, including breast cancer,
provides the necessary conditions to allow tumor growth. Vascular endothelial growth factor
(VEGF) is one of the important molecules regulating new blood vessel formations and
subsequent invasion and metastases. As a result, agents that inhibit VEGF are of substantial
interest for the treatment of advanced diseases.
This study will further the body of research of motesanib which has been shown in preclinical
pharmacology and clinical pharmacology studies to be a potent, orally bioavailable
multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively
targeting all known VEGF, platelet-derived growth factor (PDGF), and Kit receptors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University